New schizophrenia drug shows promise in early trial
NCT ID NCT01626859
First seen Jan 06, 2026 · Last updated May 09, 2026 · Updated 22 times
Summary
This study looked at how a new drug called MP-214 works in 38 adults with schizophrenia. Researchers measured safety, how the drug moves through the body, and whether it helps control symptoms over 12 weeks. The goal was to find the right dose and check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Sakai, Osaka, Japan
Conditions
Explore the condition pages connected to this study.